The tweet was deleted by the author.
But we saved everything 🙂.
Zymeworks is intensifying its engagement with the life sciences community by presenting both clinical and preclinical data from its antibody-drug conjugate (ADC) programs at this year’s AACR Annual Meeting.
The company views AACR26 as a major platform for collaboration and knowledge exchange in the field of cancer research. Key findings and program updates are being shared with industry experts and peers. Further details on the new results are available through the event’s official channels.
Zymeworks’ commitment to advancing antibody-drug conjugate research at AACR26 builds on the company’s broader strategy to showcase breakthroughs in antibody therapeutics—a focus previously highlighted during its presentations on antibody drug discovery at ESMO, as outlined in recent coverage of industry developments.